Core to Evidence-Based Health Policy
cost-effectiveness evaluation for future healthcare
C2H is the only public research organization
for official cost-effectiveness evaluation process
in Japan
C2H (Center for Outcomes Research and Economic Evaluation for Health) is an organization of National Institute of Public Health; it conducts academic analysis of cost-effectiveness evaluation from the scientific viewpoint. This website will dispatch information about cost-effectiveness evaluation in Japan. We are happy if this website contributes to evidence-based health policy (EBHP).
Tools for cost-effectiveness evaluation
Latest news
-
news
New C2H Report: Vortioxetine (Trintellix) and Ivabradine (Coralan)
Reports of the cost-effectiveness evaluation on Vortioxetine (Trintellix) and Ivabradine (Coralan) were released.
-
news
New C2H Report: Ravulizumab (Ultomiris)
Reports of the cost-effectiveness evaluation on Ravulizumab (Ultomiris) were released.
-
news
The first reports of the cost-effectiveness evaluation were released.
Reports of the cost-effectiveness evaluation on Fluticasone/Umeclidinium/Vilanterol (Trelegy) and Tisagenlecleucel (Kymriah) were released. These are our first reports since this HTA system was started from April 2019 in Japan.